All In Biotech

NDA 207154 · Almirall

Aczone

Dapsone · Topical · Sulfone

Last checked: Nov 19, 2026Latest source record: Sep 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Feb 24, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

78

24 Phase 3, 2 recruiting

FAERS reports

10,863

8,218 serious, 935 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2025.

ACZONE ® (dapsone) Gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ACZONE ® Gel, 7.5%, is a sulfone indicated for the topical treatment of acne vulgaris in patients 9 years of age and older ( 1 ).

Mechanism: The mechanism of action of dapsone gel in treating acne vulgaris is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ACZONE · DAPSONE 7.5% · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dapsone" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,306
  • drug ineffective1,166
  • methaemoglobinaemia498
  • nausea492
  • fatigue487
  • pyrexia474
  • diarrhoea426
  • rash405
  • drug reaction with eosinophilia and systemic symptoms399
  • dyspnoea392
  • pneumonia385
  • pain376

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004143
2005145
2006165
2007104
2008193
2009232
2010212
2011232
2012274
2013173
2014311
2015441
2016566
2017647
2018732
2019733
2020927
2021709
2022807
2023687
2024872
2025890
2026665

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aczone (Dapsone)

2024 spending

$78K

Beneficiaries

37

90 claims

Per beneficiary

$2,104

$12.79 per unit

View as table
YearSpending
2020$136,577
2021$200,150
2022$154,571
2023$89,314
2024$77,862

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 390 on PubMed

Sponsor: Almirall

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.